Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute myeloid leukemia.

Francis J Giles1, Armand Keating, Anthony H Goldstone

  • 1M.D. Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model for Clinician and Staff Education in the Engagement of American Indians in Genomic Research.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

A Multiregional Decentralized Clinical Trial Program to Improve Access.

JAMA network open·2026
Same author

Intraperitoneal administration of NK-92 improves survival in xenografts of early and established ovarian cancer models.

PloS one·2026
Same author

IID 2025: Physical protein interaction data with detection types, co-purified protein sets, molecular docking, and immune cell networks.

Nucleic acids research·2025
Same author

Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AML.

medRxiv : the preprint server for health sciences·2025
Same author

A molecular systems architecture of the mesenchymal stromal cell microenvironment.

Stem cells (Dayton, Ohio)·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

This review explores advances in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) pathophysiology and therapy. It covers the hematopoietic microenvironment, stem cell transplantation, molecular genetics, and novel therapeutic agents for improved patient care.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are significant hematologic malignancies.
  • Understanding the pathophysiology and developing novel therapies are crucial for improving patient outcomes.

Purpose of the Study:

  • To review recent advances in the understanding of AML and MDS pathophysiology.
  • To discuss current therapeutic strategies and future research directions for AML and MDS.
  • To highlight the role of molecular genetics and novel agents in disease management.

Main Methods:

  • Review of recent literature and clinical data.
  • Analysis of the role of the hematopoietic microenvironment in leukemia.
  • Evaluation of stem cell transplantation efficacy.

Related Experiment Videos

  • Exploration of molecular genetics and gene expression profiling.
  • Assessment of novel therapeutic agents and delivery systems.

    • Main Results:

    • The hematopoietic microenvironment plays a role in leukemia initiation and progression.
    • Stem cell transplantation remains a key therapeutic option for AML and MDS.
    • Molecular genetics aids in disease classification and target identification.
    • Novel agents and targeted therapies show promise for AML and MDS treatment.

    Conclusions:

    • Advances in understanding AML and MDS pathophysiology are informing new therapeutic strategies.
    • Personalized medicine approaches utilizing molecular genetics are essential.
    • Continued research into novel agents and delivery systems is critical for improving AML and MDS patient care.